CLY-101 (Balomenib) — Topline data
H2 2026
· Phase 2A proof of principle study in Type 2 diabetes patients first top-line data readout expected the second half of 2026Source filing
BRNS biotech catalysts & pipeline
BARINTHUS BIOTHERAPEUTICS PLC · Data as of 2026-10-25
Upcoming catalysts
VTP-1000 — Topline data
Q4 2026
Completed enrollment of 42 planned subjects in the Phase 1 AVALON trial evaluating VTP-1000 in patients with celiac disease; topline data from multiple ascending dose ("MAD") expected in the fourth quarter of 2026.Source filing